Back

Short-chain fatty acids, sodium-glucose cotransporter type 2 inhibitors, and cardiovascular benefit: a possible relationship?

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Towards optimisation of heart failure therapies Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Marcelino Cortes Garcia

Fundacion Jimenez Diaz University Hospital, Madrid (Spain)

5 More presentations in this session

Presentation thumbnail
Beta-blockers in patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: cardiovascular and respiratory outcomes
Doctor B. Beer (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Age- and sex-related differences in heart failure characteristics and treatment patterns across the ejection fraction spectrum
Doctor C. Basile (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Hyperkalemia events in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan or sodium-glucose transport protein 2 inhibitors: a single-center experience
Doctor N. Bonini (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Sequencing, intensity, and discontinuation of guideline-directed medical therapy after heart failure hospitalisation in the United States: results from the EMPACE study
Professor A. Alhamdow (DE)
Abstract Slides Video
Presentation thumbnail
Reducing the burden of advanced heart failure: a clinical and economical analysis of an intermittent Levosimendan programme
Doctor D. Inacio Cazeiro (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Towards optimisation of heart failure therapies

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Effect of sodium-glucose type 2 cotransporter inhibitors on cardiac structure and function in patients with normal ejection fraction
thumbnail
Congress Presentation
The impact of sodium glucose transporter 2 inhibitors on cardiac remodeling in a large cohort of unselected patients
thumbnail
Congress Presentation
Canagliflozin improves hemodynamic parameters by impedance cardiography and left ventricular diastolic function in patients with type 2 diabetes mellitus

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources